CDK9 inhibitor - Pipeline Insight, 2024

This “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Understanding

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview

CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.

Function -CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation.Although there are other cyclin-dependent kinases that are capable of phosphorilating the CTD, the only one that activates gene expression in a catalyst manner is CDK9.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitors- CDK9 is one of the major Pol II-directed kinases of P-TEFb. A number of small-molecule inhibitors of CDK9 kinase activity directed to the ATP-binding pocket have been developed and tested. A number of natural compounds have been identified as non-selective inhibitors of CDKs. The bis-indoles indirubins were the first human-used compounds to be identified as CDK inhibitors. CDK9 Blockade is A Potential Treatment For Pediatric Soft Tissue Sarcomas.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters

This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs

Dinaciclib: Merck & CoDinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demostrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.). The drug is currently in phase 3 of clinical trials for the treatment of Chronic lymphocytic leukaemia.

KB-0742: Kronos BioKB-0742 is a selective, orally bioavailable inhibitor of CDK9, a global regulator of transcription and a critical node in the oncogenic TRN resulting from MYC overexpression. MYC is a well-known transcription factor and cancer driver that is dysregulated in a significant proportion of human cancers, often via genomic copy number gain, or amplification. The drug is currently in phase 1/2 of clinical trials for the treatment of Solid tumours.

Alvocidib: Sumitomo Dainippon Pharma OncologyAlvocidib is an investigational, intravenously administered, small molecule cyclin-dependent kinase 9 (CDK9) inhibitor.Inhibiting CDK9 is thought to downregulate the transcription of target genes, including myeloid cell leukemia 1 (MCL-1), reducing leukemic blast viability in MCL-1-dependent, hematologic malignancies. The drug is currently in phase 2 of clinical trials for the treatment of acute myeloid leukemia.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Cyclin-Dependent Kinase 9 (CDK9) Inhibitor

There are approx. 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor. The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase 9 (CDK9) Inhibitor R&D. The therapies under development are focused on novel approaches for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Insights

• Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs?
• How many Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co
• Kronos Bio
• Sumitomo Dainippon Pharma Oncology
• AstraZeneca
• Kino Pharma
• Cyclacel Pharmaceuticals
• Bayer
• MEI Pharma
• Syros Pharmaceuticals
• BioTheryX
• Le Sun Pharmaceuticals
• NeoSome Life Sciences
• Adastra Pharmaceuticals/S*Bio
• Virostatics
• GenFleet Therapeutics
• ASINEX

Key Products

• Dinaciclib
• KB-0742
• Alvocidib
• AZD 4573
• TP 1287
• FIT 039
• BAY 1251152
• Seliciclib
• Fadraciclib
• Voruciclib
• SY 5609
• BTX A51

Research programme: cancer therapeutics- NEOS 518

• Zotiraciclib

Research programme: anticancer therapeutics- Research programme: cyclin-dependant kinases

• GFH 009

This product will be delivered within 2 business days.